Seminars in nuclear medicine最新文献

{"title":"Artificial intelligence for tumor [18F]FDG-PET imaging: Advancement and future trends—part I","authors":"Alireza Safarian MD ,&nbsp;Seyed Ali Mirshahvalad MD, MPH, FEBNM, FANMB ,&nbsp;Abolfazl Farbod MD ,&nbsp;Hadi Nasrollahi MSc ,&nbsp;Christian Pirich MD, PhD ,&nbsp;Mohsen Beheshti MD, FEBNM, FASNC","doi":"10.1053/j.semnuclmed.2025.03.003","DOIUrl":"10.1053/j.semnuclmed.2025.03.003","url":null,"abstract":"<div><div>The advent of sophisticated image analysis techniques has facilitated the extraction of increasingly complex data, such as radiomic features, from various imaging modalities, including [¹⁸F]FDG PET/CT, a well-established cornerstone of oncological imaging. Furthermore, the use of artificial intelligence (AI) algorithms has shown considerable promise in enhancing the interpretation of these quantitative parameters. Additionally, AI-driven models enable the integration of parameters from multiple imaging modalities along with clinical data, facilitating the development of comprehensive models with significant clinical impact.</div><div>However, challenges remain regarding standardization and validation of the AI-powered models, as well as their implementation in real-world clinical practice. The variability in imaging acquisition protocols, segmentation methods, and feature extraction approaches across different institutions necessitates robust harmonization efforts to ensure reproducibility and clinical utility. Moreover, the successful translation of AI models into clinical practice requires prospective validation in large cohorts, as well as seamless integration into existing workflows to assess their ability to enhance clinicians’ performance.</div><div>This review aims to provide an overview of the literature and highlight three key applications: diagnostic impact, prediction of treatment response, and long-term patient prognostication. In the first part, we will focus on head and neck, lung, breast, gastroesophageal, colorectal, and gynecological malignancies.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 3","pages":"Pages 328-344"},"PeriodicalIF":4.6,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infection and Inflammation in Nuclear Medicine Imaging: The Role of Artificial Intelligence","authors":"Margarita Kirienko ,&nbsp;Lara Cavinato ,&nbsp;Martina Sollini","doi":"10.1053/j.semnuclmed.2025.02.012","DOIUrl":"10.1053/j.semnuclmed.2025.02.012","url":null,"abstract":"<div><div>Infectious and inflammatory diseases represent a global challenge. Delayed diagnosis and treatment lead to death, disabilities and impairment of the quality of life. The detection of low-grade inflammation and occult infections remains challenging. Nuclear medicine techniques are well established in the assessment of the severity and extent of the disease. However, high-level expertise is required to process and interpret the images. Additionally, the workflows are frequently time consuming. Artificial intelligence (AI)-based techniques can be efficiently applied in this setting. We reviewed the literature to assess the state of the application of AI in nuclear medicine imaging in infectious and inflammatory diseases. We included 22 studies, which applied AI-based methods for any of the steps of their workflow. In this review we report and critically discuss the state-of-the-art knowledge on the application of AI models in Infection and Inflammation nuclear medicine imaging.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 3","pages":"Pages 396-405"},"PeriodicalIF":4.6,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of AI in Lymphoma: An Update","authors":"James Cairns BMBS, MSc, FRCR ,&nbsp;Russell Frood MBChB, PhD, FRCR ,&nbsp;Chirag Patel MBBS, FRCR ,&nbsp;Andrew Scarsbrook BMBS, PhD, FRCR","doi":"10.1053/j.semnuclmed.2025.02.007","DOIUrl":"10.1053/j.semnuclmed.2025.02.007","url":null,"abstract":"<div><div>Malignant lymphomas encompass a range of malignancies with incidence rising globally, particularly with age. In younger populations, Hodgkin and Burkitt lymphomas predominate, while older populations more commonly experience subtypes such as diffuse large B-cell, follicular, marginal zone, and mantle cell lymphomas. Positron emission tomography/computed tomography (PET/CT) using [¹⁸F] fluorodeoxyglucose (FDG) is the gold standard for staging, treatment response assessment, and prognostication in lymphoma. However, interpretation of PET/CT is complex, time-consuming, and reliant on expert imaging specialists, exacerbating challenges associated with workforce shortages worldwide. Artificial intelligence (AI) offers transformative potential across multiple aspects of PET/CT imaging in this setting.</div><div>AI applications in appointment planning have demonstrated utility in reducing nonattendance rates and improving departmental efficiency. Advanced reconstruction techniques leveraging convolutional neural networks (CNNs) enable reduced injected activities of radiopharmaceutical and patient dose whilst maintaining diagnostic accuracy, particularly benefiting younger patients requiring multiple scans. Automated segmentation tools, predominantly using 3D U-Net architectures, have improved quantification of metrics such as total metabolic tumour volume (TMTV) and total lesion glycolysis (TLG), facilitating prognostication and treatment stratification. Despite these advancements, challenges remain, including variability in segmentation performance, impact on Deauville Score interpretation, and standardization of TMTV/TLG measurements. Emerging large language models (LLMs) also show promise in enhancing PET/CT reporting, converting free-text reports into structured formats, and improving patient communication.</div><div>Further research is required to address limitations such as AI-induced errors, physiological uptake differentiation, and the integration of AI models into clinical workflows. With robust validation and harmonization, AI integration could significantly enhance lymphoma care, improving diagnostic precision, workflow efficiency, and patient outcomes.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 3","pages":"Pages 377-386"},"PeriodicalIF":4.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing CT Imaging Parameters: Implications for Diagnostic Accuracy in Nuclear Medicine","authors":"Anders F.S. Mikkelsen ,&nbsp;Jesper Thygesen ,&nbsp;Joan Fledelius","doi":"10.1053/j.semnuclmed.2025.02.008","DOIUrl":"10.1053/j.semnuclmed.2025.02.008","url":null,"abstract":"<div><div>X-ray computed tomography (CT) is an important companion modality in molecular imaging, offering attenuation correction (AC) of single-photon emission computed tomography (SPECT) - and positron emission tomography (PET)-data, topographic information in scans as well as changes in morphology in serial follow-up studies. Image quality plays a critical role in delivering an acceptable diagnosis and in medical treatment planning. Variability in protocols can present a considerable challenge in achieving consistent image quality within departments. The differences in CT scanning protocol metrics established by various manufacturers and across different generations of scanners can contribute to this issue, making the standardization of image quality a complex task. This review aims to present relevant literature herein and provide an introduction of the CT imaging parameters, including acquisition factors, reconstruction algorithms, and relevant image quality metrics, and discuss possible ways to implement a robust CT protocol review process in a nuclear medicine department. We also evaluate the potential of iterative reconstruction (IR) and deep learning (DL) for enhancing image quality and minimizing exposure doses. This article points to the need for periodic audit of image quality to guarantee that CT protocols are suited for the intended purpose. Through the creation of local diagnostic reference levels and monitoring performance through protocol management, physicians may aim at delivering high quality imaging services consistently adhering to the principles of ALARA and reduction of dose for both patients and workers.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 3","pages":"Pages 450-459"},"PeriodicalIF":4.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Status of Staging and Restaging Malignant Pleural Mesothelioma","authors":"Egesta Lopci MD, PhD","doi":"10.1053/j.semnuclmed.2025.01.003","DOIUrl":"10.1053/j.semnuclmed.2025.01.003","url":null,"abstract":"<div><div>Malignant pleural mesothelioma (MPM) is the most frequent aggressive tumor affecting the pleura, accounting for over 38,000 deaths worldwide. It originates from the mesothelial cells and is mostly associated to asbestos exposure. Depending on the extent of the disease, the management of MPM varies from surgical intervention to a combination of systemic chemotherapy, immunotherapy, and radiation therapy. Major International scientific societies provide continuous updates on proper management of the disease, including recommendations on the optimal imaging algorithms, which are crucial for determining effective treatment options and optimizing clinical outcomes. However, despite the continuous efforts to improve patients’ prognosis, median overall survival remains poor, ranging from 8 to 14 months. And even in case of initial response to treatment, local or distant recurrences represent almost a certainty, requiring appropriate imaging for the assessment of tumor sites. The aim of the present article is to illustrate the current status of imaging for staging and restaging of MPM, not forgetting most recent novelties in the diagnostic work-up of the disease.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 240-251"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter From the Editors","authors":"M Michael Sathekge MD, PhD,&nbsp;Kirsten Bouchelouche MD, DMSc","doi":"10.1053/j.semnuclmed.2025.03.001","DOIUrl":"10.1053/j.semnuclmed.2025.03.001","url":null,"abstract":"","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 153-155"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of [18F]FDG PET/CT in Monitoring of Therapy Response in Lung Cancer","authors":"Akinwale Ayeni MBChB, MMed ,&nbsp;Osayande Evbuomwan MBBS, PhD ,&nbsp;Mboyo-Di-Tamba Willy Vangu MD, PhD","doi":"10.1053/j.semnuclmed.2025.02.002","DOIUrl":"10.1053/j.semnuclmed.2025.02.002","url":null,"abstract":"<div><div>Lung cancer remains a leading cause of cancer deaths worldwide, with an all stage 5-year relative survival rate of less than 30%. Multiple treatment strategies are available and continue to evolve, with therapy primarily tailored to the type and stage of the disease. Accurate monitoring of therapy response is crucial for optimizing treatment outcomes. PET/CT imaging with [¹⁸F]FDG has become the standard of care across various phases of lung cancer management due to its ability to assess metabolic activity. This review underscores the pivotal role of [¹⁸F]FDG PET/CT in evaluating therapy response in lung cancer, particularly in non-small cell lung cancer (NSCLC). It examines conventional response criteria and their adaptations in the era of immunotherapy, highlighting the value of integrating metabolic imaging with established criteria to improve treatment assessment and guide clinical decisions. The potential of non-[¹⁸F]FDG PET tracers targeting diverse biological pathways to provide deeper insights into tumor biology, therapy response and predictive outcomes is also explored. Additionally, the emerging role of radiomics in enhancing treatment efficacy assessment and improving patient management is briefly highlighted. Despite the challenges in the routine clinical application of various metabolic response criteria, [¹⁸F]FDG PET/CT remains a crucial tool in monitoring therapy response in lung cancer. Ongoing advancements in therapeutic strategies, radiopharmaceuticals, and imaging techniques continue to drive progress in lung cancer management, promising improved patient outcomes.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 175-189"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of [18F]FDG PET/CT Radiomics and Artificial Intelligence in Clinical Decision Making in Lung Cancer: Its Current Role","authors":"Alireza Safarian MD ,&nbsp;Seyed Ali Mirshahvalad MD, MPH, FEBNM, FANMB ,&nbsp;Hadi Nasrollahi MSc ,&nbsp;Theresa Jung MD ,&nbsp;Christian Pirich MD, PhD ,&nbsp;Hossein Arabi PhD ,&nbsp;Mohsen Beheshti MD, FEBNM, FASNC","doi":"10.1053/j.semnuclmed.2025.02.006","DOIUrl":"10.1053/j.semnuclmed.2025.02.006","url":null,"abstract":"<div><div>Lung cancer remains one of the most prevalent cancers globally and the leading cause of cancer-related deaths, accounting for nearly one-fifth of all cancer fatalities. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([¹⁸F]FDG PET/CT) plays a vital role in assessing lung cancer and managing disease progression. While traditional PET/CT imaging relies on qualitative analysis and basic quantitative parameters, radiomics offers a more advanced approach to analyzing tumor phenotypes.</div><div>Recently, radiomics has gained attention for its potential to enhance the prognostic and diagnostic capabilities of [¹⁸F]FDG PET/CT in various cancers. This review explores the expanding role of [¹⁸F]FDG PET/CT-based radiomics, particularly when integrated with artificial intelligence (AI), in managing lung cancer, especially non-small cell lung cancer (NSCLC).</div><div>We review how radiomics and AI improve diagnostics, staging, tumor subtype identification, and molecular marker detection, which influence treatment decisions. Additionally, we address challenges in clinical integration, such as imaging protocol standardization, feature reproducibility, and the need for extensive prospective studies. Ultimately, radiomics and AI hold great promise for enabling more personalized and effective lung cancer treatments, potentially transforming disease management.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 156-166"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances of PET/CT in Target Delineation of Lung Cancer Before Radiation Therapy","authors":"Cedric Richlitzki MD ,&nbsp;Farkhad Manapov MD ,&nbsp;Adrien Holzgreve MD ,&nbsp;Moritz Rabe PhD ,&nbsp;Rudolf Alexander Werner MD ,&nbsp;Claus Belka MD ,&nbsp;Marcus Unterrainer MD, PhD ,&nbsp;Chukwuka Eze MD","doi":"10.1053/j.semnuclmed.2025.02.013","DOIUrl":"10.1053/j.semnuclmed.2025.02.013","url":null,"abstract":"<div><div>In the clinical management of lung cancer, radiotherapy remains a cornerstone of multimodal treatment strategies, often used alongside surgery or in combination with systemic therapies such as chemotherapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors. While conventional imaging modalities like computed tomography (CT) and magnetic resonance imaging (MRI) continue to play a central role in staging, response assessment, and radiotherapy planning, advanced imaging techniques, particularly [¹⁸F]FDG PET/CT, are being increasingly integrated into routine clinical practice. These advanced techniques address the limitations of standard imaging by providing insight into molecular and metabolic tumor characteristics, enabling precise tumor visualization, accurate target volume delineation, and early treatment response assessment. This review examines the role of radiotherapy in the multidisciplinary management of lung cancer, detailing current concepts of morphological and functional imaging for staging and treatment planning. It also highlights the growing importance of PET-based radiotherapy planning, emphasizing its contributions to target volume definition and predictive value for treatment outcomes. Recent methodological advances, including the integration of artificial intelligence (AI), radiomics, technical innovations, and novel PET ligands, are discussed, highlighting their potential to improve the precision, efficacy, and personalization of lung cancer radiotherapy planning.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 190-201"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theranostics in Lung Neuroendocrine Tumors","authors":"Indraja D. Dev MD ,&nbsp;Ameya D. Puranik DNB ,&nbsp;Nikolaos A. Trikalinos MD ,&nbsp;Bradley John Girod MD ,&nbsp;Hyun Kim MD ,&nbsp;Vikas Prasad MD","doi":"10.1053/j.semnuclmed.2025.02.010","DOIUrl":"10.1053/j.semnuclmed.2025.02.010","url":null,"abstract":"<div><div>In the last 2 decades, there has been a noticeable increase in the incidence of neuroendocrine tumors, in part due to improved understanding of pathology and/or availability of more sensitive and accurate diagnostic tests. While gastrointestinal tract and pancreas are the most common sites of origin, lung neuroendocrine tumors (LNETs) are also frequently reported and need special considerations from diagnostic as well as therapeutic aspects.</div><div>Radiopharmaceutical therapy (Theranostics) is a novel approach which utilizes a pair of diagnostic and therapeutic agents that share a common target on tumor sites. Precise treatment of the disease with minimum side effects is the principal aim of Theranostics.</div><div>It's a known fact that somatostatin receptors (SSTR) are abundantly expressed in neuroendocrine tumors. With the advent of highly specific radiopharmaceuticals targeting SSTR receptors for both diagnosis as well as treatment and other targeted therapies, management of LNETs has become less challenging. Still, there exists significant ambiguity in relation to management of LNETs with a scope of novel diagnostic and therapeutic strategies to pitch in.</div><div>This review focuses on the role of established evidence for Theranostics strategies in the management of LNETs and highlights the potential future role of newer targets which would be of promising value in addressing such rare and complex tumor biology.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 221-233"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}